Navigating The Pharma Supply Chain: Balancing Risk And Resilience In Turbulent Times

By Scott Rizzo, Senior Vice President and Chief Operating Officer, Societal CDMO

The past four years have tested the resilience of supply chains and placed strain on pharmaceutical companies trying to advance a novel therapeutic through the drug lifecycle. Supply chain is the metaphoric blood flow of a company, and if an artery is blocked, another must pick up the additional flow.

To most in the pharmaceutical industry, supply chain consists of ensuring a constant flow of items in the bill of materials (BOM), but to supply chain specialists, it is defined by four specific variables: materials, external factors, systems, and partners. Leveraging an experienced partner with a robust supply strategy can help manage the strain of a supply chain in flux and mitigate risk during the development and manufacturing processes.